Impact of a clinical pathway on appropriate empiric vancomycin use in cancer patients with febrile neutropenia.

about

Impact of a clinical pathway on appropriate empiric vancomycin use in cancer patients with febrile neutropenia.

Item

http://www.wikidata.org/entity/Q40546513

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Impact of a clinical pathway o ...... ents with febrile neutropenia.

@en

type

Item

label

Impact of a clinical pathway o ...... ents with febrile neutropenia.

@en

prefLabel

Impact of a clinical pathway o ...... ents with febrile neutropenia.

@en

P1476

Impact of a clinical pathway o ...... ents with febrile neutropenia.

@en

P2093

Jennifer Pisano

http://www.w3.org/2001/XMLSchema#string

Mildred Vicente

http://www.w3.org/2001/XMLSchema#string

Mohammad Al-Nahedh

http://www.w3.org/2001/XMLSchema#string

Natasha N Pettit

http://www.w3.org/2001/XMLSchema#string

Sandeep Parsad

http://www.w3.org/2001/XMLSchema#string

P2860

Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria.

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Effects of clinical pathways for common outpatient infections on antibiotic prescribing.

Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes

The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.

Empiric vancomycin use in febrile neutropenic oncology patients.

The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.

Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes.

Management of fever in neutropenic patients with different risks of complications.

P304

575-581

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155216668672

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Randall W Knoebel

P577

2016-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27609336

http://www.w3.org/2001/XMLSchema#string